The Psoriatic Arthritis drugs in development market research report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Psoriatic Arthritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued products.
GlobalData tracks 80 drugs in development for Psoriatic Arthritis by 61 companies/universities/institutes. The top development phase for Psoriatic Arthritis is preclinical with 25 drugs in that stage. The Psoriatic Arthritis pipeline has 80 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Psoriatic Arthritis pipeline products market are: Johnson & Johnson, Bioviz Technologies and Galapagos.
The key targets in the Psoriatic Arthritis pipeline products market include Tumor Necrosis Factor, Interleukin 17A, and Interleukin 23 Subunit Alpha.
The key mechanisms of action in the Psoriatic Arthritis pipeline product include Tumor Necrosis Factor Inhibitor with 13 drugs in Pre-Registration. The Psoriatic Arthritis pipeline products include nine routes of administration with the top ROA being Subcutaneous and nine key molecule types in the Psoriatic Arthritis pipeline products market including Monoclonal Antibody, and Small Molecule.
Psoriatic Arthritis overview
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain, and lower back pain. Risk factors include age, family history, and psoriasis. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and surgery.
For a complete picture of Psoriatic Arthritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
